Multi-target-directed phenol–triazole ligands as therapeutic agents for Alzheimer's disease. Issue 8 (16th June 2017)

• Record Type: Journal Article
• Authors: Jones, Michael R.; Mathieu, Emilie; Dyrager, Christine; Faissner, Simon; Vaillancourt, Zavier; Korshavn, Kyle J.; Lim, Mi Hee; Ramamoorthy, Ayyalusamy; Wee Yong, V.; Tsutsui, Shigeki; Stys, Peter K.; Storr, Tim
• Is Part Of: Chemical science. Volume 8:Issue 8(2017)
• Page Start: 5636
• Page End: 5643
• Publication Date: 2017-06-16
• Subjects: Chemistry -- Periodicals; 540.5
• DOI: 10.1039/c7sc01269a
• Languages: English
• ISSNs: 2041-6520

Abstract

Abstract : A series of multi-target-directed ligands are described that bind Cu, act as antioxidants, modulate Aβ peptide aggregation, and abolish Aβ toxicity in primary neurons. Abstract : Alzheimer's disease (AD) is a multifactorial disease that is characterized by the formation of intracellular neurofibrillary tangles and extracellular amyloid-β (Aβ) plaque deposits. Increased oxidative stress, metal ion dysregulation, and the formation of toxic Aβ peptide oligomers are all considered to contribute to the etiology of AD. In this work we have developed a series of ligands that are multi-target-directed in order to address several disease properties. 2-(1-(3-Hydroxypropyl)-1 H -1, 2, 3-triazol-4-yl)phenol (POH ), 2-(1-(2-morpholinoethyl)-1 H -1, 2, 3-triazol-4-yl)phenol (PMorph ), and 2-(1-(2-thiomorpholinoethyl)-1 H -1, 2, 3-triazol-4-yl)phenol (PTMorph ) have been synthesized and screened for their antioxidant capacity, Cu-binding affinity, interaction with the Aβ peptide and modulation of Aβ peptide aggregation, and the ability to limit Aβ1–42 -induced neurotoxicity in human neuronal culture. The synthetic protocol and structural variance incorporated via click chemistry, highlights the influence of R-group modification on ligand-Aβ interactions and neuroprotective effects. Overall, this study demonstrates that the phenol–triazole ligand scaffold can target multiple factors associated with AD, thus warranting further therapeutic development.